ATLANTA, May 8 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. , a biopharmaceutical company dedicated to the development of innovative gene transfer therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease, will release its first quarter 2006 financial results on Monday, May 15, 2006. Corautus will also host a conference call to discuss the results and provide an update of its therapeutic development program at 11:00 A.M. Eastern time on May 15. Richard Otto, President and Chief Executive Officer of Corautus, will host the call.
To access the live webcast, please log on to the Corautus’ website at www.corautus.com and go to the Investor Relations section. Alternatively, domestic callers may participate in the conference call by dialing (888) 396- 2356, and international callers may participate in the conference call by dialing (617) 847-8709. The participant passcode for access to the conference is “Corautus”. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call. Domestic callers can access the replay by dialing (888) 286-8010, and international callers can access the replay by dialing (617) 801-6888; the PIN access number is 56918015.
About Corautus Genetics Inc.
Corautus Genetics Inc. is a clinical-stage biopharmaceutical company dedicated to the development of gene transfer therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease. Corautus is currently developing and testing a gene transfer product using the Vascular Endothelial Growth Factor-2 (VEGF-2) gene to promote therapeutic angiogenesis in ischemic muscle. Corautus has a strategic alliance with Boston Scientific Corporation to develop, commercialize and distribute the VEGF-2 gene therapy products. For more information, please visit http://www.corautus.com.
Forward-Looking Statement
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements that address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our GENASIS clinical trial or any future trials, including the likelihood of obtaining positive data from such trials, potential benefits from manufacturing agreements, the potential benefits from previous clinical trials, potential benefits from Phase I trials we are supporting in the areas of critical limb ischemia and diabetic neuropathy, future results of operations or our financial condition, adequacy of funding, benefits from the alliance with Boston Scientific, research, development and commercialization of our product candidates, anticipated trends in our business, manufacture of sufficient and acceptable quantities of our proposed products, approval of our product candidates, meeting additional capital requirements, and other risks that could cause actual results to differ materially. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus’ 2005 Annual Report on Form 10-K which was filed on March 20, 2006. All forward-looking statements included in this document are based on information available to Corautus on the date hereof, and Corautus assumes no obligation to update any such forward-looking statements.
Company Contact: Michael K. Steele (404) 526-6212 msteele@corautus.com Investor Relations Contacts: Lippert/Heilshorn & Associates Kim Sutton Golodetz Kgolodetz@lhai.com Anne Marie Fields Afields@lhai.com 212-838-3777
Corautus Genetics Inc.
CONTACT: Michael K. Steele of Corautus Genetics Inc., +1-404-526-6212, ormsteele@corautus.com; or Investor Relations, Kim Sutton Golodetz,Kgolodetz@lhai.com, or Anne Marie Fields, Afields@lhai.com, ofLippert-Heilshorn & Associates, +1-212-838-3777
Web site: http://www.corautus.com/
